|
Consolidated balance sheets (USD '000) |
30.9.2003 |
31.12.2002 |
Change |
|
|
|
|
|
|
|
|
|
|
|
Fixed assets |
65,712 |
32,836 |
100% |
|
Current assets |
36,019 |
38,589 |
-7% |
|
Total assets |
101,731 |
71,425 |
42% |
|
|
|
|
|
|
Equity |
46,900 |
39,861 |
18% |
|
Long-term liabilities |
38,791 |
14,627 |
165% |
|
Current liabilities |
16,040 |
16,937 |
-5% |
|
Total equity and liabilities |
101,731 |
71,425 |
42% |
3rd Quarter Results - Best ever
| Source: Novo Nordisk A/S
Strong growth in Earnings and Cash flow. Full-year EBITDA Outlook upgraded to DKK 15.0bn
Highlights 3Q 2003
Good performance in TDC Mobile International and TDC Switzerland
Outlook 2003 for EBITDA upgraded to DKK 15.0bn from DKK 14.8bn.
Outlook 2003 for net revenues and net income reaffirmed2
Balance Sheet at End of September:
Download the report
Recommended Reading
-
Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.
Read More -
Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent
Read More